La CANDIDOSI RICORRENTE è una condizione che "accompagna" la vita di numerose donne. Lo stress, la composizione del microbiota, lo stile di vita e soprattutto lo stile nutrizionale giocano un ruolo importante a livello preventivo. Come dimostra questo interessante studio della durata di due anni recentemente pubblicato sul Journal of Biological Regulators and Homeostatic Agents l'utilizzo ragionato di un fitocomplesso ad hoc può essere uno strumento ulteriore nelle mani del medico per affrontare la candidosi vulvovaginale ricorrente.
J Biol Regul Homeost Agents. 2013 Jul-Sep;27(3):875-82.
Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole.
Chopra V, Marotta F, Kumari A, Bishier MP, He F, Zerbinati N, Agarwal C, Naito Y, Tomella C, Sharma A, Solimene U.
SourceReGenera Research Group for Intervention in Aging, Milano, Italy.
The aim of the present study was to assess the clinical efficacy of a one week/month treatment with a phytocompound with antimycotic properties (K-712, with following 100 mg composition: 10 mg of oleoresin from Pseudowintera colorata at 30 percent concentration in Polygodial together with trace amounts of Olea europea) in recurrent vulvo-vaginal candidiasis (RVVC), as compared to once a week treatment with an azole drug for 24 months follow up. This prospective randomized study involving 122 women (19 to 63 years old) with a history of proven episodes of RVVC in the prior 12 months. Patients were allocated in two treatment groups of 61 patients each and given A) Itraconazole 200 mg orally once a week or B) 1 tab twice a day of K-712 for one week/month. Each treatment schedule was well tolerated with 19 patients in the azole group complaining of transient mild symptoms (nausea, abdominal discomfort, unpleasant taste), while only 3 patients on K-712 reported slight dyspepsia. The number of relapses was significantly lower in the K-712-treated group as compared to the itraconazole-group (22 vs 39, p less than 0.05). Moreover, the former group showed a significantly decreased number of cases resistant or dose-dependent susceptible as compared to group A (p less than 0.05 vs itraconazole) and the same occurred for the occurrence of non-albicans species (group A 64.1 percent vs group B 31.8 percent, p less than 0.05). The overall mycological cure at the end of the 2-year study showed a comparable benefit between the two groups. From these data it appears that the present antifungal phytonutrient is equally effective as itraconazole in the overall treatment of RVVC over a 2-year follow-up, but yielding a significantly better prophylactic effect and also maintenance benefit with lower relapse rate, antifungal susceptibility and growth of azole-resistant species.